nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—NQO2—Imatinib—hematologic cancer	0.164	0.306	CbGbCtD
Dabigatran etexilate—CES2—Irinotecan—hematologic cancer	0.141	0.264	CbGbCtD
Dabigatran etexilate—ABCB1—hematologic cancer	0.102	1	CbGaD
Dabigatran etexilate—CES1—Irinotecan—hematologic cancer	0.0491	0.0917	CbGbCtD
Dabigatran etexilate—UGT1A9—Irinotecan—hematologic cancer	0.0298	0.0557	CbGbCtD
Dabigatran etexilate—UGT2B7—Epirubicin—hematologic cancer	0.029	0.0542	CbGbCtD
Dabigatran etexilate—ABCB1—Lenalidomide—hematologic cancer	0.0173	0.0322	CbGbCtD
Dabigatran etexilate—ABCB1—Daunorubicin—hematologic cancer	0.0101	0.0189	CbGbCtD
Dabigatran etexilate—ABCB1—Alitretinoin—hematologic cancer	0.00991	0.0185	CbGbCtD
Dabigatran etexilate—ABCB1—Imatinib—hematologic cancer	0.00775	0.0145	CbGbCtD
Dabigatran etexilate—ABCB1—Nilotinib—hematologic cancer	0.00704	0.0131	CbGbCtD
Dabigatran etexilate—ABCB1—Vinorelbine—hematologic cancer	0.00698	0.013	CbGbCtD
Dabigatran etexilate—ABCB1—Dasatinib—hematologic cancer	0.00622	0.0116	CbGbCtD
Dabigatran etexilate—ABCB1—Mitoxantrone—hematologic cancer	0.00615	0.0115	CbGbCtD
Dabigatran etexilate—ABCB1—Betamethasone—hematologic cancer	0.00548	0.0102	CbGbCtD
Dabigatran etexilate—ABCB1—Gemcitabine—hematologic cancer	0.00543	0.0101	CbGbCtD
Dabigatran etexilate—ABCB1—Prednisolone—hematologic cancer	0.0054	0.0101	CbGbCtD
Dabigatran etexilate—ABCB1—Prednisone—hematologic cancer	0.0051	0.00953	CbGbCtD
Dabigatran etexilate—ABCB1—Irinotecan—hematologic cancer	0.00484	0.00903	CbGbCtD
Dabigatran etexilate—ABCB1—Vinblastine—hematologic cancer	0.0043	0.00803	CbGbCtD
Dabigatran etexilate—ABCB1—Vincristine—hematologic cancer	0.00423	0.00789	CbGbCtD
Dabigatran etexilate—ABCB1—Cisplatin—hematologic cancer	0.00394	0.00736	CbGbCtD
Dabigatran etexilate—ABCB1—Etoposide—hematologic cancer	0.00388	0.00723	CbGbCtD
Dabigatran etexilate—ABCB1—Dexamethasone—hematologic cancer	0.00319	0.00595	CbGbCtD
Dabigatran etexilate—ABCB1—Doxorubicin—hematologic cancer	0.00264	0.00493	CbGbCtD
Dabigatran etexilate—ABCB1—Methotrexate—hematologic cancer	0.00256	0.00478	CbGbCtD
Dabigatran etexilate—CES2—hematopoietic system—hematologic cancer	0.00227	0.0726	CbGeAlD
Dabigatran etexilate—F2—hematopoietic system—hematologic cancer	0.00203	0.0652	CbGeAlD
Dabigatran etexilate—CES1—hematopoietic system—hematologic cancer	0.00187	0.0598	CbGeAlD
Dabigatran etexilate—CES2—gonad—hematologic cancer	0.00172	0.0552	CbGeAlD
Dabigatran etexilate—CES2—blood—hematologic cancer	0.0015	0.0481	CbGeAlD
Dabigatran etexilate—CES2—bone marrow—hematologic cancer	0.00145	0.0466	CbGeAlD
Dabigatran etexilate—F2—blood—hematologic cancer	0.00135	0.0432	CbGeAlD
Dabigatran etexilate—NQO2—blood—hematologic cancer	0.00134	0.043	CbGeAlD
Dabigatran etexilate—CES2—lung—hematologic cancer	0.00132	0.0422	CbGeAlD
Dabigatran etexilate—F2—bone marrow—hematologic cancer	0.0013	0.0418	CbGeAlD
Dabigatran etexilate—NQO2—bone marrow—hematologic cancer	0.0013	0.0416	CbGeAlD
Dabigatran etexilate—CES2—testis—hematologic cancer	0.00124	0.0398	CbGeAlD
Dabigatran etexilate—UGT2B7—testis—hematologic cancer	0.00124	0.0398	CbGeAlD
Dabigatran etexilate—CES1—blood—hematologic cancer	0.00124	0.0396	CbGeAlD
Dabigatran etexilate—F2—lung—hematologic cancer	0.00118	0.0378	CbGeAlD
Dabigatran etexilate—NQO2—lung—hematologic cancer	0.00118	0.0377	CbGeAlD
Dabigatran etexilate—NQO2—testis—hematologic cancer	0.00111	0.0356	CbGeAlD
Dabigatran etexilate—CES1—lung—hematologic cancer	0.00108	0.0347	CbGeAlD
Dabigatran etexilate—CES1—testis—hematologic cancer	0.00102	0.0328	CbGeAlD
Dabigatran etexilate—CES2—lymph node—hematologic cancer	0.0009	0.0289	CbGeAlD
Dabigatran etexilate—NQO2—lymph node—hematologic cancer	0.000804	0.0258	CbGeAlD
Dabigatran etexilate—CES1—lymph node—hematologic cancer	0.000741	0.0238	CbGeAlD
Dabigatran etexilate—ABCB1—hematopoietic system—hematologic cancer	0.000437	0.014	CbGeAlD
Dabigatran etexilate—ABCB1—gonad—hematologic cancer	0.000332	0.0107	CbGeAlD
Dabigatran etexilate—ABCB1—blood—hematologic cancer	0.000289	0.00928	CbGeAlD
Dabigatran etexilate—ABCB1—bone marrow—hematologic cancer	0.00028	0.00898	CbGeAlD
Dabigatran etexilate—ABCB1—lung—hematologic cancer	0.000254	0.00814	CbGeAlD
Dabigatran etexilate—ABCB1—testis—hematologic cancer	0.000239	0.00768	CbGeAlD
Dabigatran etexilate—ABCB1—lymph node—hematologic cancer	0.000174	0.00557	CbGeAlD
Dabigatran etexilate—Vomiting—Vincristine—hematologic cancer	3.09e-05	0.000138	CcSEcCtD
Dabigatran etexilate—Urticaria—Prednisolone—hematologic cancer	3.09e-05	0.000138	CcSEcCtD
Dabigatran etexilate—Asthenia—Cisplatin—hematologic cancer	3.09e-05	0.000137	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Methotrexate—hematologic cancer	3.08e-05	0.000137	CcSEcCtD
Dabigatran etexilate—Fatigue—Triamcinolone—hematologic cancer	3.08e-05	0.000137	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Epirubicin—hematologic cancer	3.07e-05	0.000137	CcSEcCtD
Dabigatran etexilate—Rash—Vincristine—hematologic cancer	3.07e-05	0.000137	CcSEcCtD
Dabigatran etexilate—Dermatitis—Vincristine—hematologic cancer	3.06e-05	0.000136	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Epirubicin—hematologic cancer	3.06e-05	0.000136	CcSEcCtD
Dabigatran etexilate—Haematuria—Doxorubicin—hematologic cancer	3.06e-05	0.000136	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Epirubicin—hematologic cancer	3.06e-05	0.000136	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Epirubicin—hematologic cancer	3.05e-05	0.000136	CcSEcCtD
Dabigatran etexilate—Headache—Vincristine—hematologic cancer	3.05e-05	0.000136	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Prednisone—hematologic cancer	3.04e-05	0.000135	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Doxorubicin—hematologic cancer	3.03e-05	0.000135	CcSEcCtD
Dabigatran etexilate—Hypotension—Dexamethasone—hematologic cancer	3.03e-05	0.000135	CcSEcCtD
Dabigatran etexilate—Hypotension—Betamethasone—hematologic cancer	3.03e-05	0.000135	CcSEcCtD
Dabigatran etexilate—Nausea—Carmustine—hematologic cancer	3.03e-05	0.000135	CcSEcCtD
Dabigatran etexilate—Epistaxis—Doxorubicin—hematologic cancer	3.02e-05	0.000135	CcSEcCtD
Dabigatran etexilate—Angiopathy—Methotrexate—hematologic cancer	3.01e-05	0.000134	CcSEcCtD
Dabigatran etexilate—Vomiting—Mitoxantrone—hematologic cancer	3.01e-05	0.000134	CcSEcCtD
Dabigatran etexilate—Vomiting—Irinotecan—hematologic cancer	3.01e-05	0.000134	CcSEcCtD
Dabigatran etexilate—Sinusitis—Doxorubicin—hematologic cancer	3.01e-05	0.000134	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Methotrexate—hematologic cancer	3e-05	0.000134	CcSEcCtD
Dabigatran etexilate—Nausea—Alitretinoin—hematologic cancer	3e-05	0.000134	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Methotrexate—hematologic cancer	2.99e-05	0.000133	CcSEcCtD
Dabigatran etexilate—Hypertension—Prednisone—hematologic cancer	2.99e-05	0.000133	CcSEcCtD
Dabigatran etexilate—Rash—Irinotecan—hematologic cancer	2.99e-05	0.000133	CcSEcCtD
Dabigatran etexilate—Rash—Mitoxantrone—hematologic cancer	2.99e-05	0.000133	CcSEcCtD
Dabigatran etexilate—Dermatitis—Irinotecan—hematologic cancer	2.98e-05	0.000133	CcSEcCtD
Dabigatran etexilate—Dermatitis—Mitoxantrone—hematologic cancer	2.98e-05	0.000133	CcSEcCtD
Dabigatran etexilate—Headache—Mitoxantrone—hematologic cancer	2.97e-05	0.000132	CcSEcCtD
Dabigatran etexilate—Headache—Irinotecan—hematologic cancer	2.97e-05	0.000132	CcSEcCtD
Dabigatran etexilate—Nausea—Ifosfamide—hematologic cancer	2.96e-05	0.000132	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	2.95e-05	0.000132	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Betamethasone—hematologic cancer	2.95e-05	0.000132	CcSEcCtD
Dabigatran etexilate—Arthralgia—Prednisone—hematologic cancer	2.95e-05	0.000131	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Cisplatin—hematologic cancer	2.94e-05	0.000131	CcSEcCtD
Dabigatran etexilate—Vomiting—Gemcitabine—hematologic cancer	2.93e-05	0.000131	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	2.93e-05	0.00013	CcSEcCtD
Dabigatran etexilate—Rash—Gemcitabine—hematologic cancer	2.91e-05	0.00013	CcSEcCtD
Dabigatran etexilate—Dermatitis—Gemcitabine—hematologic cancer	2.91e-05	0.000129	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Etoposide—hematologic cancer	2.9e-05	0.000129	CcSEcCtD
Dabigatran etexilate—Malnutrition—Methotrexate—hematologic cancer	2.89e-05	0.000129	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Doxorubicin—hematologic cancer	2.89e-05	0.000129	CcSEcCtD
Dabigatran etexilate—Headache—Gemcitabine—hematologic cancer	2.89e-05	0.000129	CcSEcCtD
Dabigatran etexilate—Nausea—Vincristine—hematologic cancer	2.89e-05	0.000129	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Epirubicin—hematologic cancer	2.89e-05	0.000129	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Doxorubicin—hematologic cancer	2.88e-05	0.000128	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Prednisolone—hematologic cancer	2.86e-05	0.000128	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Betamethasone—hematologic cancer	2.85e-05	0.000127	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Dexamethasone—hematologic cancer	2.85e-05	0.000127	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Doxorubicin—hematologic cancer	2.84e-05	0.000127	CcSEcCtD
Dabigatran etexilate—Urticaria—Triamcinolone—hematologic cancer	2.84e-05	0.000126	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Doxorubicin—hematologic cancer	2.83e-05	0.000126	CcSEcCtD
Dabigatran etexilate—Asthenia—Etoposide—hematologic cancer	2.83e-05	0.000126	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Doxorubicin—hematologic cancer	2.83e-05	0.000126	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Prednisone—hematologic cancer	2.82e-05	0.000126	CcSEcCtD
Dabigatran etexilate—Angiopathy—Epirubicin—hematologic cancer	2.82e-05	0.000126	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Doxorubicin—hematologic cancer	2.82e-05	0.000126	CcSEcCtD
Dabigatran etexilate—Nausea—Irinotecan—hematologic cancer	2.81e-05	0.000125	CcSEcCtD
Dabigatran etexilate—Nausea—Mitoxantrone—hematologic cancer	2.81e-05	0.000125	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Epirubicin—hematologic cancer	2.81e-05	0.000125	CcSEcCtD
Dabigatran etexilate—Infection—Prednisone—hematologic cancer	2.81e-05	0.000125	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Epirubicin—hematologic cancer	2.8e-05	0.000125	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Betamethasone—hematologic cancer	2.8e-05	0.000125	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Dexamethasone—hematologic cancer	2.8e-05	0.000125	CcSEcCtD
Dabigatran etexilate—Back pain—Methotrexate—hematologic cancer	2.8e-05	0.000125	CcSEcCtD
Dabigatran etexilate—Fatigue—Dexamethasone—hematologic cancer	2.8e-05	0.000125	CcSEcCtD
Dabigatran etexilate—Fatigue—Betamethasone—hematologic cancer	2.8e-05	0.000125	CcSEcCtD
Dabigatran etexilate—Pruritus—Etoposide—hematologic cancer	2.79e-05	0.000124	CcSEcCtD
Dabigatran etexilate—Shock—Prednisone—hematologic cancer	2.78e-05	0.000124	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Prednisone—hematologic cancer	2.77e-05	0.000123	CcSEcCtD
Dabigatran etexilate—Skin disorder—Prednisone—hematologic cancer	2.74e-05	0.000122	CcSEcCtD
Dabigatran etexilate—Nausea—Gemcitabine—hematologic cancer	2.74e-05	0.000122	CcSEcCtD
Dabigatran etexilate—Vomiting—Cisplatin—hematologic cancer	2.73e-05	0.000122	CcSEcCtD
Dabigatran etexilate—Rash—Cisplatin—hematologic cancer	2.71e-05	0.000121	CcSEcCtD
Dabigatran etexilate—Dermatitis—Cisplatin—hematologic cancer	2.71e-05	0.000121	CcSEcCtD
Dabigatran etexilate—Malnutrition—Epirubicin—hematologic cancer	2.71e-05	0.000121	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Etoposide—hematologic cancer	2.7e-05	0.00012	CcSEcCtD
Dabigatran etexilate—Anaemia—Methotrexate—hematologic cancer	2.67e-05	0.000119	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Doxorubicin—hematologic cancer	2.67e-05	0.000119	CcSEcCtD
Dabigatran etexilate—Flatulence—Epirubicin—hematologic cancer	2.67e-05	0.000119	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Dexamethasone—hematologic cancer	2.65e-05	0.000118	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Betamethasone—hematologic cancer	2.65e-05	0.000118	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Triamcinolone—hematologic cancer	2.63e-05	0.000117	CcSEcCtD
Dabigatran etexilate—Back pain—Epirubicin—hematologic cancer	2.62e-05	0.000117	CcSEcCtD
Dabigatran etexilate—Angiopathy—Doxorubicin—hematologic cancer	2.61e-05	0.000116	CcSEcCtD
Dabigatran etexilate—Dizziness—Etoposide—hematologic cancer	2.61e-05	0.000116	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Doxorubicin—hematologic cancer	2.6e-05	0.000116	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Doxorubicin—hematologic cancer	2.59e-05	0.000115	CcSEcCtD
Dabigatran etexilate—Urticaria—Betamethasone—hematologic cancer	2.58e-05	0.000115	CcSEcCtD
Dabigatran etexilate—Urticaria—Dexamethasone—hematologic cancer	2.58e-05	0.000115	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Prednisone—hematologic cancer	2.57e-05	0.000115	CcSEcCtD
Dabigatran etexilate—Dizziness—Prednisolone—hematologic cancer	2.57e-05	0.000114	CcSEcCtD
Dabigatran etexilate—Asthenia—Triamcinolone—hematologic cancer	2.56e-05	0.000114	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Betamethasone—hematologic cancer	2.56e-05	0.000114	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Dexamethasone—hematologic cancer	2.56e-05	0.000114	CcSEcCtD
Dabigatran etexilate—Nausea—Cisplatin—hematologic cancer	2.55e-05	0.000114	CcSEcCtD
Dabigatran etexilate—Pruritus—Triamcinolone—hematologic cancer	2.53e-05	0.000113	CcSEcCtD
Dabigatran etexilate—Cough—Methotrexate—hematologic cancer	2.52e-05	0.000112	CcSEcCtD
Dabigatran etexilate—Vomiting—Etoposide—hematologic cancer	2.51e-05	0.000112	CcSEcCtD
Dabigatran etexilate—Malnutrition—Doxorubicin—hematologic cancer	2.5e-05	0.000112	CcSEcCtD
Dabigatran etexilate—Anaemia—Epirubicin—hematologic cancer	2.5e-05	0.000111	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Prednisone—hematologic cancer	2.49e-05	0.000111	CcSEcCtD
Dabigatran etexilate—Rash—Etoposide—hematologic cancer	2.48e-05	0.000111	CcSEcCtD
Dabigatran etexilate—Dermatitis—Etoposide—hematologic cancer	2.48e-05	0.000111	CcSEcCtD
Dabigatran etexilate—Headache—Etoposide—hematologic cancer	2.47e-05	0.00011	CcSEcCtD
Dabigatran etexilate—Flatulence—Doxorubicin—hematologic cancer	2.47e-05	0.00011	CcSEcCtD
Dabigatran etexilate—Arthralgia—Methotrexate—hematologic cancer	2.46e-05	0.00011	CcSEcCtD
Dabigatran etexilate—Chest pain—Methotrexate—hematologic cancer	2.46e-05	0.00011	CcSEcCtD
Dabigatran etexilate—Rash—Prednisolone—hematologic cancer	2.45e-05	0.000109	CcSEcCtD
Dabigatran etexilate—Dermatitis—Prednisolone—hematologic cancer	2.45e-05	0.000109	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	2.45e-05	0.000109	CcSEcCtD
Dabigatran etexilate—Fatigue—Prednisone—hematologic cancer	2.43e-05	0.000108	CcSEcCtD
Dabigatran etexilate—Headache—Prednisolone—hematologic cancer	2.43e-05	0.000108	CcSEcCtD
Dabigatran etexilate—Syncope—Epirubicin—hematologic cancer	2.43e-05	0.000108	CcSEcCtD
Dabigatran etexilate—Back pain—Doxorubicin—hematologic cancer	2.42e-05	0.000108	CcSEcCtD
Dabigatran etexilate—Constipation—Prednisone—hematologic cancer	2.42e-05	0.000108	CcSEcCtD
Dabigatran etexilate—Palpitations—Epirubicin—hematologic cancer	2.39e-05	0.000107	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Epirubicin—hematologic cancer	2.38e-05	0.000106	CcSEcCtD
Dabigatran etexilate—Dizziness—Triamcinolone—hematologic cancer	2.36e-05	0.000105	CcSEcCtD
Dabigatran etexilate—Cough—Epirubicin—hematologic cancer	2.36e-05	0.000105	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Methotrexate—hematologic cancer	2.36e-05	0.000105	CcSEcCtD
Dabigatran etexilate—Infection—Methotrexate—hematologic cancer	2.34e-05	0.000104	CcSEcCtD
Dabigatran etexilate—Nausea—Etoposide—hematologic cancer	2.34e-05	0.000104	CcSEcCtD
Dabigatran etexilate—Hypertension—Epirubicin—hematologic cancer	2.34e-05	0.000104	CcSEcCtD
Dabigatran etexilate—Asthenia—Betamethasone—hematologic cancer	2.33e-05	0.000104	CcSEcCtD
Dabigatran etexilate—Asthenia—Dexamethasone—hematologic cancer	2.33e-05	0.000104	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Methotrexate—hematologic cancer	2.31e-05	0.000103	CcSEcCtD
Dabigatran etexilate—Anaemia—Doxorubicin—hematologic cancer	2.31e-05	0.000103	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Methotrexate—hematologic cancer	2.31e-05	0.000103	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Prednisone—hematologic cancer	2.31e-05	0.000103	CcSEcCtD
Dabigatran etexilate—Nausea—Prednisolone—hematologic cancer	2.31e-05	0.000103	CcSEcCtD
Dabigatran etexilate—Arthralgia—Epirubicin—hematologic cancer	2.3e-05	0.000103	CcSEcCtD
Dabigatran etexilate—Chest pain—Epirubicin—hematologic cancer	2.3e-05	0.000103	CcSEcCtD
Dabigatran etexilate—Pruritus—Betamethasone—hematologic cancer	2.29e-05	0.000102	CcSEcCtD
Dabigatran etexilate—Pruritus—Dexamethasone—hematologic cancer	2.29e-05	0.000102	CcSEcCtD
Dabigatran etexilate—Skin disorder—Methotrexate—hematologic cancer	2.29e-05	0.000102	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	2.29e-05	0.000102	CcSEcCtD
Dabigatran etexilate—Vomiting—Triamcinolone—hematologic cancer	2.27e-05	0.000101	CcSEcCtD
Dabigatran etexilate—Rash—Triamcinolone—hematologic cancer	2.25e-05	0.0001	CcSEcCtD
Dabigatran etexilate—Dermatitis—Triamcinolone—hematologic cancer	2.25e-05	0.0001	CcSEcCtD
Dabigatran etexilate—Syncope—Doxorubicin—hematologic cancer	2.25e-05	0.0001	CcSEcCtD
Dabigatran etexilate—Urticaria—Prednisone—hematologic cancer	2.24e-05	9.99e-05	CcSEcCtD
Dabigatran etexilate—Headache—Triamcinolone—hematologic cancer	2.24e-05	9.97e-05	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Prednisone—hematologic cancer	2.23e-05	9.94e-05	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Dexamethasone—hematologic cancer	2.22e-05	9.88e-05	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Betamethasone—hematologic cancer	2.22e-05	9.88e-05	CcSEcCtD
Dabigatran etexilate—Palpitations—Doxorubicin—hematologic cancer	2.21e-05	9.86e-05	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Epirubicin—hematologic cancer	2.21e-05	9.84e-05	CcSEcCtD
Dabigatran etexilate—Hypotension—Methotrexate—hematologic cancer	2.21e-05	9.82e-05	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Doxorubicin—hematologic cancer	2.2e-05	9.8e-05	CcSEcCtD
Dabigatran etexilate—Infection—Epirubicin—hematologic cancer	2.19e-05	9.77e-05	CcSEcCtD
Dabigatran etexilate—Cough—Doxorubicin—hematologic cancer	2.19e-05	9.73e-05	CcSEcCtD
Dabigatran etexilate—Shock—Epirubicin—hematologic cancer	2.17e-05	9.68e-05	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Epirubicin—hematologic cancer	2.17e-05	9.65e-05	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Epirubicin—hematologic cancer	2.16e-05	9.63e-05	CcSEcCtD
Dabigatran etexilate—Hypertension—Doxorubicin—hematologic cancer	2.16e-05	9.63e-05	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Methotrexate—hematologic cancer	2.15e-05	9.58e-05	CcSEcCtD
Dabigatran etexilate—Skin disorder—Epirubicin—hematologic cancer	2.15e-05	9.56e-05	CcSEcCtD
Dabigatran etexilate—Dizziness—Betamethasone—hematologic cancer	2.14e-05	9.55e-05	CcSEcCtD
Dabigatran etexilate—Dizziness—Dexamethasone—hematologic cancer	2.14e-05	9.55e-05	CcSEcCtD
Dabigatran etexilate—Arthralgia—Doxorubicin—hematologic cancer	2.13e-05	9.5e-05	CcSEcCtD
Dabigatran etexilate—Chest pain—Doxorubicin—hematologic cancer	2.13e-05	9.5e-05	CcSEcCtD
Dabigatran etexilate—Nausea—Triamcinolone—hematologic cancer	2.12e-05	9.46e-05	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.12e-05	9.43e-05	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Methotrexate—hematologic cancer	2.1e-05	9.37e-05	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Prednisone—hematologic cancer	2.08e-05	9.27e-05	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Methotrexate—hematologic cancer	2.08e-05	9.25e-05	CcSEcCtD
Dabigatran etexilate—Hypotension—Epirubicin—hematologic cancer	2.06e-05	9.19e-05	CcSEcCtD
Dabigatran etexilate—Vomiting—Dexamethasone—hematologic cancer	2.06e-05	9.18e-05	CcSEcCtD
Dabigatran etexilate—Vomiting—Betamethasone—hematologic cancer	2.06e-05	9.18e-05	CcSEcCtD
Dabigatran etexilate—Rash—Betamethasone—hematologic cancer	2.04e-05	9.11e-05	CcSEcCtD
Dabigatran etexilate—Rash—Dexamethasone—hematologic cancer	2.04e-05	9.11e-05	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Doxorubicin—hematologic cancer	2.04e-05	9.1e-05	CcSEcCtD
Dabigatran etexilate—Dermatitis—Dexamethasone—hematologic cancer	2.04e-05	9.1e-05	CcSEcCtD
Dabigatran etexilate—Dermatitis—Betamethasone—hematologic cancer	2.04e-05	9.1e-05	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.04e-05	9.08e-05	CcSEcCtD
Dabigatran etexilate—Fatigue—Methotrexate—hematologic cancer	2.03e-05	9.06e-05	CcSEcCtD
Dabigatran etexilate—Headache—Betamethasone—hematologic cancer	2.03e-05	9.05e-05	CcSEcCtD
Dabigatran etexilate—Headache—Dexamethasone—hematologic cancer	2.03e-05	9.05e-05	CcSEcCtD
Dabigatran etexilate—Infection—Doxorubicin—hematologic cancer	2.03e-05	9.04e-05	CcSEcCtD
Dabigatran etexilate—Asthenia—Prednisone—hematologic cancer	2.03e-05	9.03e-05	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Epirubicin—hematologic cancer	2.01e-05	8.96e-05	CcSEcCtD
Dabigatran etexilate—Shock—Doxorubicin—hematologic cancer	2.01e-05	8.96e-05	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Doxorubicin—hematologic cancer	2e-05	8.93e-05	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Doxorubicin—hematologic cancer	2e-05	8.91e-05	CcSEcCtD
Dabigatran etexilate—Pruritus—Prednisone—hematologic cancer	2e-05	8.9e-05	CcSEcCtD
Dabigatran etexilate—Skin disorder—Doxorubicin—hematologic cancer	1.99e-05	8.84e-05	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Epirubicin—hematologic cancer	1.97e-05	8.77e-05	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Epirubicin—hematologic cancer	1.94e-05	8.66e-05	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Prednisone—hematologic cancer	1.93e-05	8.61e-05	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Methotrexate—hematologic cancer	1.93e-05	8.6e-05	CcSEcCtD
Dabigatran etexilate—Nausea—Dexamethasone—hematologic cancer	1.93e-05	8.58e-05	CcSEcCtD
Dabigatran etexilate—Nausea—Betamethasone—hematologic cancer	1.93e-05	8.58e-05	CcSEcCtD
Dabigatran etexilate—Hypotension—Doxorubicin—hematologic cancer	1.91e-05	8.51e-05	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.91e-05	8.49e-05	CcSEcCtD
Dabigatran etexilate—Fatigue—Epirubicin—hematologic cancer	1.9e-05	8.48e-05	CcSEcCtD
Dabigatran etexilate—Constipation—Epirubicin—hematologic cancer	1.89e-05	8.41e-05	CcSEcCtD
Dabigatran etexilate—Urticaria—Methotrexate—hematologic cancer	1.88e-05	8.35e-05	CcSEcCtD
Dabigatran etexilate—Dizziness—Prednisone—hematologic cancer	1.87e-05	8.32e-05	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Methotrexate—hematologic cancer	1.87e-05	8.31e-05	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.86e-05	8.29e-05	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Doxorubicin—hematologic cancer	1.82e-05	8.12e-05	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Epirubicin—hematologic cancer	1.81e-05	8.05e-05	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Doxorubicin—hematologic cancer	1.8e-05	8.01e-05	CcSEcCtD
Dabigatran etexilate—Vomiting—Prednisone—hematologic cancer	1.8e-05	8e-05	CcSEcCtD
Dabigatran etexilate—Rash—Prednisone—hematologic cancer	1.78e-05	7.93e-05	CcSEcCtD
Dabigatran etexilate—Dermatitis—Prednisone—hematologic cancer	1.78e-05	7.92e-05	CcSEcCtD
Dabigatran etexilate—Headache—Prednisone—hematologic cancer	1.77e-05	7.88e-05	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.76e-05	7.86e-05	CcSEcCtD
Dabigatran etexilate—Fatigue—Doxorubicin—hematologic cancer	1.76e-05	7.85e-05	CcSEcCtD
Dabigatran etexilate—Urticaria—Epirubicin—hematologic cancer	1.75e-05	7.82e-05	CcSEcCtD
Dabigatran etexilate—Constipation—Doxorubicin—hematologic cancer	1.75e-05	7.79e-05	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Epirubicin—hematologic cancer	1.75e-05	7.78e-05	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Methotrexate—hematologic cancer	1.74e-05	7.75e-05	CcSEcCtD
Dabigatran etexilate—Asthenia—Methotrexate—hematologic cancer	1.69e-05	7.54e-05	CcSEcCtD
Dabigatran etexilate—Nausea—Prednisone—hematologic cancer	1.68e-05	7.47e-05	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.67e-05	7.44e-05	CcSEcCtD
Dabigatran etexilate—Pruritus—Methotrexate—hematologic cancer	1.67e-05	7.44e-05	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Epirubicin—hematologic cancer	1.63e-05	7.25e-05	CcSEcCtD
Dabigatran etexilate—Urticaria—Doxorubicin—hematologic cancer	1.62e-05	7.23e-05	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Doxorubicin—hematologic cancer	1.62e-05	7.2e-05	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Methotrexate—hematologic cancer	1.61e-05	7.19e-05	CcSEcCtD
Dabigatran etexilate—Asthenia—Epirubicin—hematologic cancer	1.58e-05	7.06e-05	CcSEcCtD
Dabigatran etexilate—Pruritus—Epirubicin—hematologic cancer	1.56e-05	6.96e-05	CcSEcCtD
Dabigatran etexilate—Dizziness—Methotrexate—hematologic cancer	1.56e-05	6.95e-05	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Epirubicin—hematologic cancer	1.51e-05	6.73e-05	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Doxorubicin—hematologic cancer	1.51e-05	6.71e-05	CcSEcCtD
Dabigatran etexilate—Vomiting—Methotrexate—hematologic cancer	1.5e-05	6.68e-05	CcSEcCtD
Dabigatran etexilate—Rash—Methotrexate—hematologic cancer	1.49e-05	6.63e-05	CcSEcCtD
Dabigatran etexilate—Dermatitis—Methotrexate—hematologic cancer	1.49e-05	6.62e-05	CcSEcCtD
Dabigatran etexilate—Headache—Methotrexate—hematologic cancer	1.48e-05	6.59e-05	CcSEcCtD
Dabigatran etexilate—Asthenia—Doxorubicin—hematologic cancer	1.47e-05	6.53e-05	CcSEcCtD
Dabigatran etexilate—Dizziness—Epirubicin—hematologic cancer	1.46e-05	6.51e-05	CcSEcCtD
Dabigatran etexilate—Pruritus—Doxorubicin—hematologic cancer	1.45e-05	6.44e-05	CcSEcCtD
Dabigatran etexilate—Vomiting—Epirubicin—hematologic cancer	1.4e-05	6.26e-05	CcSEcCtD
Dabigatran etexilate—Nausea—Methotrexate—hematologic cancer	1.4e-05	6.25e-05	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Doxorubicin—hematologic cancer	1.4e-05	6.23e-05	CcSEcCtD
Dabigatran etexilate—Rash—Epirubicin—hematologic cancer	1.39e-05	6.2e-05	CcSEcCtD
Dabigatran etexilate—Dermatitis—Epirubicin—hematologic cancer	1.39e-05	6.2e-05	CcSEcCtD
Dabigatran etexilate—Headache—Epirubicin—hematologic cancer	1.38e-05	6.16e-05	CcSEcCtD
Dabigatran etexilate—Dizziness—Doxorubicin—hematologic cancer	1.35e-05	6.02e-05	CcSEcCtD
Dabigatran etexilate—Nausea—Epirubicin—hematologic cancer	1.31e-05	5.84e-05	CcSEcCtD
Dabigatran etexilate—Vomiting—Doxorubicin—hematologic cancer	1.3e-05	5.79e-05	CcSEcCtD
Dabigatran etexilate—Rash—Doxorubicin—hematologic cancer	1.29e-05	5.74e-05	CcSEcCtD
Dabigatran etexilate—Dermatitis—Doxorubicin—hematologic cancer	1.29e-05	5.73e-05	CcSEcCtD
Dabigatran etexilate—Headache—Doxorubicin—hematologic cancer	1.28e-05	5.7e-05	CcSEcCtD
Dabigatran etexilate—Nausea—Doxorubicin—hematologic cancer	1.21e-05	5.41e-05	CcSEcCtD
Dabigatran etexilate—UGT1A9—Metabolism—ABCG2—hematologic cancer	1.17e-05	0.000109	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—NUP214—hematologic cancer	1.17e-05	0.000109	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTGER4—hematologic cancer	1.17e-05	0.000109	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—LCK—hematologic cancer	1.16e-05	0.000109	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—AKT1—hematologic cancer	1.16e-05	0.000108	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MAP2K1—hematologic cancer	1.15e-05	0.000107	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ENO2—hematologic cancer	1.15e-05	0.000107	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—ABCG2—hematologic cancer	1.14e-05	0.000107	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—H3F3A—hematologic cancer	1.14e-05	0.000106	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CD44—hematologic cancer	1.14e-05	0.000106	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—NQO1—hematologic cancer	1.14e-05	0.000106	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTT1—hematologic cancer	1.11e-05	0.000104	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PRKCZ—hematologic cancer	1.11e-05	0.000103	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CDA—hematologic cancer	1.1e-05	0.000103	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	1.09e-05	0.000102	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—FGF2—hematologic cancer	1.09e-05	0.000102	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CB—hematologic cancer	1.09e-05	0.000102	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—SDC1—hematologic cancer	1.09e-05	0.000102	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CG—hematologic cancer	1.08e-05	0.000101	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—EP300—hematologic cancer	1.08e-05	0.000101	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CYCS—hematologic cancer	1.08e-05	0.000101	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—HSP90AA1—hematologic cancer	1.07e-05	9.99e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PARP1—hematologic cancer	1.07e-05	9.99e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PC—hematologic cancer	1.06e-05	9.88e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FBXW7—hematologic cancer	1.05e-05	9.83e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—SRC—hematologic cancer	1.05e-05	9.82e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	1.04e-05	9.7e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—BCL2—hematologic cancer	1.04e-05	9.69e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HDAC2—hematologic cancer	1.03e-05	9.64e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CXCR4—hematologic cancer	1.03e-05	9.64e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	1.02e-05	9.58e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—VEGFA—hematologic cancer	1.02e-05	9.57e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—hematologic cancer	1.02e-05	9.55e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GBA—hematologic cancer	1.02e-05	9.54e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SLC35B2—hematologic cancer	1.02e-05	9.54e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—TFRC—hematologic cancer	1.02e-05	9.54e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—NRAS—hematologic cancer	1.01e-05	9.45e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CBL—hematologic cancer	1e-05	9.39e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL3—hematologic cancer	9.94e-06	9.29e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CG—hematologic cancer	9.82e-06	9.18e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	9.8e-06	9.16e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTPN1—hematologic cancer	9.77e-06	9.14e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—MAPK3—hematologic cancer	9.68e-06	9.05e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PTPN11—hematologic cancer	9.65e-06	9.02e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—RASGRP1—hematologic cancer	9.61e-06	8.99e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HSP90AA1—hematologic cancer	9.58e-06	8.96e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SYK—hematologic cancer	9.58e-06	8.96e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CD—hematologic cancer	9.51e-06	8.89e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSTP1—hematologic cancer	9.48e-06	8.86e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PTEN—hematologic cancer	9.4e-06	8.79e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TGFB1—hematologic cancer	9.39e-06	8.78e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CREB1—hematologic cancer	9.35e-06	8.74e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—MTAP—hematologic cancer	9.33e-06	8.73e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—hematologic cancer	9.33e-06	8.72e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—STAT1—hematologic cancer	9.24e-06	8.64e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CD44—hematologic cancer	9.24e-06	8.64e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NQO1—hematologic cancer	9.24e-06	8.64e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CCL2—hematologic cancer	9.14e-06	8.55e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—hematologic cancer	9.14e-06	8.55e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL6R—hematologic cancer	9.12e-06	8.52e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	9.04e-06	8.46e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3R1—hematologic cancer	8.98e-06	8.39e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ABCB1—hematologic cancer	8.97e-06	8.39e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—EP300—hematologic cancer	8.97e-06	8.39e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—hematologic cancer	8.9e-06	8.32e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—hematologic cancer	8.88e-06	8.3e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYCS—hematologic cancer	8.74e-06	8.17e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—JAK2—hematologic cancer	8.72e-06	8.16e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSTM1—hematologic cancer	8.71e-06	8.15e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—NCOR1—hematologic cancer	8.71e-06	8.15e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—KRAS—hematologic cancer	8.7e-06	8.13e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—MAP2K1—hematologic cancer	8.69e-06	8.12e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—HSP90AA1—hematologic cancer	8.68e-06	8.12e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—GRB2—hematologic cancer	8.64e-06	8.08e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CD—hematologic cancer	8.63e-06	8.07e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PDGFA—hematologic cancer	8.62e-06	8.06e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—hematologic cancer	8.61e-06	8.05e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—hematologic cancer	8.59e-06	8.03e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—CYCS—hematologic cancer	8.56e-06	8e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KITLG—hematologic cancer	8.5e-06	7.95e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—hematologic cancer	8.4e-06	7.85e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—FHL2—hematologic cancer	8.32e-06	7.78e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—STAT5A—hematologic cancer	8.31e-06	7.77e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CB—hematologic cancer	8.28e-06	7.75e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN2B—hematologic cancer	8.24e-06	7.7e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—hematologic cancer	8.19e-06	7.66e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—AGRN—hematologic cancer	8.16e-06	7.63e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3R1—hematologic cancer	8.15e-06	7.62e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PIK3CA—hematologic cancer	7.99e-06	7.47e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CD86—hematologic cancer	7.97e-06	7.45e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—hematologic cancer	7.96e-06	7.45e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—JAK2—hematologic cancer	7.92e-06	7.41e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HES1—hematologic cancer	7.86e-06	7.35e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	7.82e-06	7.31e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NCOR1—hematologic cancer	7.81e-06	7.3e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—hematologic cancer	7.76e-06	7.25e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—IDH2—hematologic cancer	7.73e-06	7.23e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HMMR—hematologic cancer	7.73e-06	7.23e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TP53—hematologic cancer	7.73e-06	7.23e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CSF2—hematologic cancer	7.72e-06	7.22e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FGF1—hematologic cancer	7.72e-06	7.22e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTP1—hematologic cancer	7.7e-06	7.2e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—MTHFR—hematologic cancer	7.7e-06	7.2e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FOXO1—hematologic cancer	7.61e-06	7.12e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—IL2—hematologic cancer	7.61e-06	7.11e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PDGFRB—hematologic cancer	7.6e-06	7.1e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CB—hematologic cancer	7.52e-06	7.03e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PDGFRA—hematologic cancer	7.48e-06	6.99e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—JAK1—hematologic cancer	7.46e-06	6.97e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PRKCG—hematologic cancer	7.46e-06	6.97e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	7.45e-06	6.97e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—HRAS—hematologic cancer	7.39e-06	6.91e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK3—hematologic cancer	7.34e-06	6.86e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ABCB1—hematologic cancer	7.29e-06	6.82e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ARNTL—hematologic cancer	7.27e-06	6.8e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—hematologic cancer	7.14e-06	6.67e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—hematologic cancer	7.12e-06	6.66e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NCOR1—hematologic cancer	7.08e-06	6.62e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTM1—hematologic cancer	7.08e-06	6.62e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ACP5—hematologic cancer	7.07e-06	6.61e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CA9—hematologic cancer	7.07e-06	6.61e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NCOR2—hematologic cancer	6.98e-06	6.53e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL2RA—hematologic cancer	6.96e-06	6.51e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL2—hematologic cancer	6.91e-06	6.46e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TERT—hematologic cancer	6.88e-06	6.44e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PDGFB—hematologic cancer	6.72e-06	6.28e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—IDH1—hematologic cancer	6.65e-06	6.22e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—hematologic cancer	6.65e-06	6.21e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CA—hematologic cancer	6.63e-06	6.2e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—hematologic cancer	6.59e-06	6.16e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTO1—hematologic cancer	6.58e-06	6.15e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ABCC3—hematologic cancer	6.58e-06	6.15e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—TXN—hematologic cancer	6.58e-06	6.15e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TSC2—hematologic cancer	6.57e-06	6.14e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—AKT1—hematologic cancer	6.53e-06	6.1e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CG—hematologic cancer	6.47e-06	6.05e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SPHK1—hematologic cancer	6.44e-06	6.02e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FGFR3—hematologic cancer	6.32e-06	5.91e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—MTHFR—hematologic cancer	6.26e-06	5.85e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MAPK14—hematologic cancer	6.25e-06	5.85e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—UGT1A1—hematologic cancer	6.18e-06	5.78e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ESR1—hematologic cancer	6.14e-06	5.74e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FN1—hematologic cancer	6.06e-06	5.67e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—hematologic cancer	6.06e-06	5.66e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SLC22A1—hematologic cancer	6.01e-06	5.62e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CRABP1—hematologic cancer	6.01e-06	5.62e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CREBBP—hematologic cancer	6e-06	5.61e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—BAD—hematologic cancer	5.99e-06	5.6e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NFKBIA—hematologic cancer	5.99e-06	5.6e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NOTCH1—hematologic cancer	5.93e-06	5.55e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ALOX5—hematologic cancer	5.86e-06	5.48e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—hematologic cancer	5.86e-06	5.48e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CD80—hematologic cancer	5.81e-06	5.43e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KIT—hematologic cancer	5.8e-06	5.42e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CG—hematologic cancer	5.8e-06	5.42e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—NRAS—hematologic cancer	5.8e-06	5.42e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTPN11—hematologic cancer	5.7e-06	5.33e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CD—hematologic cancer	5.69e-06	5.32e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NUP98—hematologic cancer	5.68e-06	5.31e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ALB—hematologic cancer	5.61e-06	5.25e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—MAPK3—hematologic cancer	5.55e-06	5.19e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CREB1—hematologic cancer	5.52e-06	5.16e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	5.51e-06	5.16e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ADCY7—hematologic cancer	5.51e-06	5.15e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NCOA3—hematologic cancer	5.51e-06	5.15e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NUP214—hematologic cancer	5.47e-06	5.12e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—BRAF—hematologic cancer	5.45e-06	5.1e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—AKT1—hematologic cancer	5.42e-06	5.07e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCL2—hematologic cancer	5.4e-06	5.05e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL6R—hematologic cancer	5.39e-06	5.04e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CREBBP—hematologic cancer	5.38e-06	5.03e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3R1—hematologic cancer	5.37e-06	5.02e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ABCG2—hematologic cancer	5.36e-06	5.01e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—MTR—hematologic cancer	5.36e-06	5.01e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CG—hematologic cancer	5.26e-06	4.92e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ENO2—hematologic cancer	5.26e-06	4.92e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MAP2K1—hematologic cancer	5.13e-06	4.8e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CD—hematologic cancer	5.1e-06	4.77e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTT1—hematologic cancer	5.1e-06	4.77e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CA—hematologic cancer	5.05e-06	4.72e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—KRAS—hematologic cancer	4.99e-06	4.67e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—SDC1—hematologic cancer	4.98e-06	4.66e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CB—hematologic cancer	4.96e-06	4.63e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	4.95e-06	4.63e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FGF2—hematologic cancer	4.88e-06	4.56e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CREBBP—hematologic cancer	4.87e-06	4.56e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3R1—hematologic cancer	4.81e-06	4.5e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	4.77e-06	4.46e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—JAK2—hematologic cancer	4.68e-06	4.38e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CD—hematologic cancer	4.62e-06	4.32e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CA—hematologic cancer	4.59e-06	4.29e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MDM2—hematologic cancer	4.57e-06	4.27e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ALB—hematologic cancer	4.56e-06	4.27e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	4.47e-06	4.18e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MTOR—hematologic cancer	4.44e-06	4.16e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CB—hematologic cancer	4.44e-06	4.16e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3R1—hematologic cancer	4.36e-06	4.08e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PTEN—hematologic cancer	4.28e-06	4.01e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—HRAS—hematologic cancer	4.24e-06	3.97e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NQO1—hematologic cancer	4.24e-06	3.96e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CD44—hematologic cancer	4.24e-06	3.96e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN1B—hematologic cancer	4.17e-06	3.9e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—AKT1—hematologic cancer	4.13e-06	3.86e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CASP3—hematologic cancer	4.09e-06	3.82e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—EP300—hematologic cancer	4.09e-06	3.82e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL2—hematologic cancer	4.08e-06	3.82e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL6—hematologic cancer	4.06e-06	3.8e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CB—hematologic cancer	4.03e-06	3.77e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYCS—hematologic cancer	4.01e-06	3.75e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HSP90AA1—hematologic cancer	3.98e-06	3.73e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCND1—hematologic cancer	3.98e-06	3.72e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—JUN—hematologic cancer	3.97e-06	3.71e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN1A—hematologic cancer	3.85e-06	3.6e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PTEN—hematologic cancer	3.84e-06	3.59e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MAPK8—hematologic cancer	3.76e-06	3.51e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—AKT1—hematologic cancer	3.75e-06	3.5e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—EP300—hematologic cancer	3.66e-06	3.42e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SRC—hematologic cancer	3.56e-06	3.33e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTP1—hematologic cancer	3.53e-06	3.3e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PTEN—hematologic cancer	3.48e-06	3.25e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—VEGFA—hematologic cancer	3.47e-06	3.24e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—STAT3—hematologic cancer	3.43e-06	3.21e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—NRAS—hematologic cancer	3.43e-06	3.2e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—EP300—hematologic cancer	3.32e-06	3.1e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MAPK3—hematologic cancer	3.28e-06	3.07e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NCOR1—hematologic cancer	3.25e-06	3.04e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTM1—hematologic cancer	3.25e-06	3.04e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MYC—hematologic cancer	3.19e-06	2.98e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TGFB1—hematologic cancer	3.18e-06	2.98e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CA—hematologic cancer	3.02e-06	2.83e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KRAS—hematologic cancer	2.95e-06	2.76e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—MTHFR—hematologic cancer	2.87e-06	2.68e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CA—hematologic cancer	2.71e-06	2.53e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TP53—hematologic cancer	2.62e-06	2.45e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HRAS—hematologic cancer	2.51e-06	2.34e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—AKT1—hematologic cancer	2.47e-06	2.31e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CA—hematologic cancer	2.46e-06	2.3e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CG—hematologic cancer	2.41e-06	2.25e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL6—hematologic cancer	2.4e-06	2.24e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CREBBP—hematologic cancer	2.24e-06	2.09e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AKT1—hematologic cancer	2.21e-06	2.07e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CD—hematologic cancer	2.12e-06	1.98e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ALB—hematologic cancer	2.09e-06	1.96e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—AKT1—hematologic cancer	2.01e-06	1.88e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3R1—hematologic cancer	2e-06	1.87e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.85e-06	1.73e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PTEN—hematologic cancer	1.6e-06	1.49e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—EP300—hematologic cancer	1.52e-06	1.42e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CA—hematologic cancer	1.13e-06	1.05e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—AKT1—hematologic cancer	9.2e-07	8.6e-06	CbGpPWpGaD
